Ketamine is used as an anesthetic to put patients to sleep during surgery and medical procedures. In recent years, it has also been used in small doses to treat severe depression and chronic pain when other treatments haven't worked.[2] Ketalar is currently approved and in use across 117 indications[4].[1]
Ketalar is one of 1220 small molecule programs targeting Treatment Resistant Depression. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Competition
744 competitors in Breast Cancer
Ketalar
Lexiscan
Voltaren
Zolymbus
Blenoxane
Methylthioninium Chloride
MS Contin
Duragesic-100
MS Contin
Spravato
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Feb 19, 1970
KETALAR
NDA NDA016812
May 14, 1976
KETALAR
NDA NDA016812
Jan 28, 1977
KETALAR
NDA NDA016812
May 16, 1977
KETALAR
NDA NDA016812
May 16, 1977
KETALAR
NDA NDA016812
Jul 5, 1977
KETALAR
NDA NDA016812
Apr 4, 1980
KETALAR
NDA NDA016812
Apr 4, 1980
KETALAR
NDA NDA016812
Aug 18, 1980
KETALAR
NDA NDA016812
Jan 1, 1982
KETALAR
NDA NDA016812
Jun 11, 1982
KETALAR
NDA NDA016812
Feb 7, 1989
KETALAR
NDA NDA016812
Nov 29, 1994
KETALAR
NDA NDA016812
Sep 5, 1997
KETALAR
NDA NDA016812
Nov 17, 1998
KETALAR
NDA NDA016812
Mar 14, 2000
KETALAR
NDA NDA016812
Mar 29, 2000
KETALAR
NDA NDA016812
Feb 14, 2001
KETALAR
NDA NDA016812
Nov 14, 2002
KETALAR
NDA NDA016812
Mar 7, 2012
KETALAR
NDA NDA016812
Apr 27, 2017
KETALAR
NDA NDA016812
Aug 7, 2018
KETALAR
NDA NDA016812
Aug 24, 2020
KETALAR
NDA NDA016812
Jun 3, 2022
KETALAR
NDA NDA016812
Aug 23, 2022
KETALAR
NDA NDA016812
Oct 29, 2025
KETALAR
NDA NDA016812
Mar 20, 2026
KETALAR
NDA NDA016812
Mar 23, 2026
KETALAR
NDA NDA016812
Sources
Details